Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 42.55% | 53.87% | 37.64% | 45.17% | 44.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.55% | 53.87% | 37.64% | 45.17% | 44.69% |
| Cost of Revenue | 40.28% | 38.58% | 12.79% | 32.91% | 34.42% |
| Gross Profit | 43.04% | 57.45% | 43.55% | 48.06% | 47.11% |
| SG&A Expenses | 24.79% | 32.37% | 32.19% | 28.65% | 53.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.69% | 32.10% | 22.47% | 21.35% | 33.06% |
| Operating Income | 62.32% | 86.82% | 61.28% | 97.70% | 67.11% |
| Income Before Tax | 64.07% | 355.33% | 92.66% | 36.28% | 100.83% |
| Income Tax Expenses | 159.11% | 166.93% | 102.82% | 137.65% | 96.96% |
| Earnings from Continuing Operations | 50.52% | 475.34% | 90.78% | 23.02% | 101.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.52% | 475.34% | 90.78% | 23.02% | 101.39% |
| EBIT | 62.32% | 86.82% | 61.28% | 97.70% | 67.11% |
| EBITDA | 58.85% | 78.81% | 57.35% | 87.21% | 62.57% |
| EPS Basic | 51.39% | 477.97% | 91.42% | 23.31% | 101.57% |
| Normalized Basic EPS | 61.39% | 88.04% | 60.37% | 98.49% | 80.23% |
| EPS Diluted | 51.39% | 480.37% | 91.77% | 23.39% | 101.86% |
| Normalized Diluted EPS | 61.39% | 88.48% | 60.62% | 98.74% | 80.23% |
| Average Basic Shares Outstanding | -0.57% | -0.46% | -0.33% | -0.23% | -0.09% |
| Average Diluted Shares Outstanding | -0.57% | -0.69% | -0.49% | -0.35% | -0.09% |
| Dividend Per Share | 15.38% | 15.38% | 15.38% | 15.38% | 15.04% |
| Payout Ratio | -0.23% | -0.80% | -0.40% | -0.06% | -0.43% |